The largest database of trusted experimental protocols

Suppositories

Suppositories are solid dosage forms designed for insertion into body cavities, usually the rectum or vagina, to deliver medications or other substances.
They are commonly used for the treatment of various conditions, such as constipation, hemorrhoids, and vaginal infections.
Suppositories are formulated to melt or dissolve at body temperature, allowing the active ingredients to be absorbed and exert their therapeutic effects.
Researchers and developers in the field of suppositories can utilize advanced technologies like AI-driven insights from PubCompare.ai to streamline their research and development processes, idenfity the most effective suppositories products and protocols, and elevate their work to new heights.

Most cited protocols related to «Suppositories»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2014
Diagnosis Morphine Opioids Patients Suppositories Therapeutics
The Partner Project was a randomised study that recruited 420 HIV-seroconcordant and serodiscordant Zambian couples 18 years of age or older between January 2003 and June 2006. Of these, both partners participated and completed a baseline assessment of sexual and demographic data. A total of 392 couples were assessed from which additional analyses were conducted utilising data from a sample of participants with less than consistent condom use (N=83 couples). Couples were excluded if they reported no sexual activity within the last month.
Study candidates currently in heterosexual couple relationships were recruited from VCT clinics in the University Teaching Hospital, community health centres and non-governmental organisations. Randomisation was used to distribute the influence of VCT across both conditions. Couples were enrolled following HIV counselling and testing and provided verification of seropositive status of one or both members of the couple. Couples were screened for eligibility, i.e. currently sexually active, 18 years or older, couple relationship (minimum of 6 months as a couple to reduce potential attrition due to separation), and at least one member HIV seropositive.
Recruiters, assessors and interventionists were multilingual (e.g. Bemba, Nyanja, English) and assessments were conducted in the preferred language of the participant; the majority of assessments were conducted in English. Intervention sessions were conducted using a combination of Bemba, Nyanja and English, due to the mixture of audience language (73 local and 3 primary regional languages in Zambia); all study staff were fluent in the three intervention languages. All participants received monetary compensation for their travel expenses.
Participants (i) completed an informed consent; (ii) were tested for other sexually transmitted infections (STDs; HIV, antibody test, syphilis, serum; chlamydia and gonorrhoea, Gram stain) and vaginal infections (bacterial vaginosis, candidiasis, trichomonas), and penile infections; (iii) completed a baseline assessment of demographic information and sexual behaviour; and (iv) were randomised to condition (see Fig. 1).
All sessions were gender-concordant groups. All female participants completed the multiple (3) session intervention; their male partners were randomised into multiple (3) session and single (1) session group intervention arms to assess the relative influence of increased participation by male partners on sexual risk reduction within the couple. Both arms were introduced to and provided with the same number of male (18) and female (6) condoms per couple; multiple session group intervention participants were also provided with a lubricant pack of three vaginal lubricants to serve as placebos to assess product acceptability for future potential introduction of microbicides (Astroglide® & KY® gels, Lubrin® suppositories). Participants were notified of their STD or screening results and were provided with appropriate treatment prior to receiving study products. For those participants who were lost to followup, recruiters conducted home visits in the community to encourage study involvement and if the participant withdrew, establish the reason for attrition. In the event of permanent loss of one member of a couple (e.g. illness, death, estrangement), individual participants were encouraged to continue to participate. The primary causes for attrition over 12 months (15%) were moving to another location, (75%) employment, (10%) illness, (5%) divorce, and death (5%).
Publication 2009
Antibodies Arm, Upper Astroglide Bacterial Vaginosis Candidiasis Chlamydia Condoms Eligibility Determination Gels Gonorrhea Gram's stain Heterosexuals Infection lubrin Males Microbicides Penis Placebos Serum Sexually Transmitted Diseases Sexual Partners Suppositories Syphilis Tooth Attrition Trichomonas Vagina Visit, Home Woman

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2014
Arthritis Back Pain Care, Ambulatory Diagnosis Familial Atypical Mole-Malignant Melanoma Syndrome Hospice Care Malignant Neoplasms Migraine Disorders Mucous Membrane Neck Pain Neuralgia Opioids Parenteral Nutrition Patients Suppositories
All procedure-related interventions were dictated by the performing endoscopist. Immediately after the procedure, if the endoscopist and research coordinator determined that inclusion criteria had been met, patients were randomly assigned to receive either two 50-mg indomethacin suppositories or two identical-appearing placebo suppositories. The randomization schedule, which was stratified according to study center, was generated centrally at the University of Michigan.
The suppositories were administered immediately after ERCP while the patient was still in the procedure room. The rectal route was selected on the basis of available pilot data suggesting that only rectal NSAIDs are effective in preventing post-ERCP pancreatitis, perhaps owing to more rapid and complete bioavailability than with oral administration.10 (link),18 (link) The indomethacin suppositories were purchased from two vendors: G&W Laboratories and Custom Med Apothecary. Formal potency testing confirmed that the vendors provided indomethacin suppositories that were pharmacodynamically equivalent (Analytic Research Laboratories).
Publication 2012
Administration, Oral Anti-Inflammatory Agents, Non-Steroidal Endoscopic Retrograde Cholangiopancreatography Indomethacin Pancreatitis Patients Placebos Rectum Suppositories

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Antibiotics ARID1A protein, human Artesunate Asian Persons BLOOD Buttocks Capsule Dietary Fiber Eligibility Determination Ethics Committees Inpatient Malaria Negroid Races Only Child Patient Admission Patient Discharge Patients Placebos Quinine Rectum Suppositories Traditional Medicine Practitioners Transmission, Communicable Disease

Most recents protocols related to «Suppositories»

Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200 mg/day or subcutaneous tocilizumab 162 mg/biweekly switched from MTX ± other csDMARDs throughout the study period. Patients with moderate renal dysfunction (estimated glomerular filtration rate 30–60 mL/min/1.73 m2) will be allowed to be administered filgotinib 100 mg/day.
All patients must continue to receive the same doses of corticosteroid that they were receiving before providing consent throughout the study period. During the study period, the following treatments are prohibited: administration of a bDMARD, except tocilizumab, or JAK inhibitor, except for filgotinib; concomitant use of an immunosuppressant (azathioprine, cyclophosphamide, cyclosporine), csDMARD, or oral corticosteroids equivalent to more than 5 mg/day of prednisolone, in addition to intra-articular corticosteroid injections at joints, and nonsteroidal anti-inflammatory drug suppositories. During the study period, the dose of any oral nonsteroidal anti-inflammatory drug can be modified within the range of its approved doses in Japan.
Full text: Click here
Publication 2023
Adrenal Cortex Hormones Anti-Inflammatory Agents, Non-Steroidal Azathioprine Cyclophosphamide Cyclosporine filgotinib Glomerular Filtration Rate Immunosuppressive Agents Intra-Articular Injections Kidney Failure Kinase Inhibitor, Janus Patients Prednisolone Suppositories tocilizumab
Sections of the 3D printed suppositories were imaged using a Phenom Pro Desktop Scanning Electron Microscope (Thermo Fisher Scientific, UK) at 10 kV accelerating voltage. Each sample was placed on a self-adhesive carbon disc, mounted on a 25 mm aluminium stub, and coated with 25 nm of gold via a sputter coater. An optical navigation camera was used to attain surface images of the suppositories.
Full text: Click here
Publication 2023
Aluminum Carbon Gold Scanning Electron Microscopy Suppositories
Each suppository (n = 3) was dissolved in 100 mL of 0.1 M phosphate buffer (pH 8.0) at 37 ± 0.5 °C under continuous magnetic stirring at 100 rpm until complete dissolution was achieved. 1 mL aliquots were withdrawn and diluted by half using absolute ethanol. Samples were then filtered via a 0.22 μm syringe filter (Sigma Aldrich, UK). The total amount of drug in each sample was quantified using a Hewlett Packard 1260II Series HPLC system (Agilent Technologies, UK). The assay involved injecting 20 μL of each sample through an Eclipse plus C18 column, 150 mm × 4.6 mm (Zorbax, Agilent Technologies, UK) at 40 °C. The mobile phase was comprised of A) methanol and B) purified water and was pumped at a flow rate of 1 mL/min. The gradient elution was as follows: 50% A from 0 to 4 min, followed by 50–80% A from 4 to 4.10 min, then kept at 80% A from 4.10 to 8 min and finally 80–50% A from 8 to 12 min. The eluents were screened at a wavelength of 254 nm.
Full text: Click here
Publication 2023
Biological Assay Buffers Ethanol High-Performance Liquid Chromatographies Methanol Pharmaceutical Preparations Phosphates Suppositories Syringes
50 mg of each suppository was placed in 100 mL of purified water under magnetic stirring at 100 rpm until the emulsions were formed. Then, a drop of diluted SEDDS was deposited on the carbon-formvar film grid, stained by 1% aqueous solution of phosphotungstic acid and observed after drying. TEM images of the emulsion droplets were captured using a CM120 Philips Biotwin transmission electron microscope (Eindhoven, The Netherlands).
Full text: Click here
Publication 2023
Carbon Emulsions Formvar Phosphotungstic Acid Suppositories Transmission Electron Microscopy
Pre-selected proportions of lipid excipients, co-solvent, and drugs were weighed in preparation for compounding of the formulations (Table 1). Each TOF10-BUD4 suppository contained 10 mg tofacitinib citrate and 4 mg budesonide, whereas each TOF5-BUD2 suppository contained 5 mg tofacitinib citrate and 2 mg budesonide. 4 and 2 mg budesonide dosing in suppositories has been previously reported in the literature (Kruis et al., 2019 (link); Kruis et al., 2022 ). Tofacitinib citrate is currently available in 2 oral doses; 10 and 5 mg. As there are currently no rectal forms of tofacitinib citrate commercially available (Electronic Medicines Compendium, 2022 ), its UC oral doses were adopted in this study.

Summary of the compositions of the formulations used for printing the suppositories.

Table 1
FormulationTofacitinib citrate (%w/w)Budesonide (%w/w)Gelucire® 44/14 (%w/w)Coconut oil (%w/w)N,N-DMA (%w/w)
TOF10-BUD40.490.1975.4618.865.00
TOF5-BUD20.240.1075.7318.935.00
Selected ratios of excipients were melted at 75 °C in a 100 mL glass beaker, positioned on a Super-Nuova Multi-Position Digital Stirring Hotplate (Thermo Fisher Scientific, Massachusetts, USA) under magnetic stirring (500 rpm). Once the mixture was completely melted, selected amounts of the drugs were added, whilst keeping the mixture under magnetic stirring until complete solubilisation of the drugs was achieved. Upon solubilisation, the formulation was directly transferred to a 20 mL Injekt® disposable syringe (Braun, Germany) and placed in a −20 °C freezer to solidify. Once solid, a tapered 0.024″ - 0.61 mm extrusion tip (Fisnar, UK) was attached to the end of the syringe which was then positioned into the SSE printhead of the M3DIMAKER 2 3D printer (FabRx Ltd., UK). Previously prepared 3D models (Dimensions: 12 mm × 36 mm) of the suppositories were transformed into .gcode files by means of Cura software (v 15.04.6, Ultimaker Utrecht, Netherlands) and printed using the following parameters: 29 °C printing temperature; 0.5 mm layer height; 2.4 mm shell thickness; 25 mm/s flow speed. As the printing temperature was close to room temperature, an evaporative air cooler (Igenix, UK) was placed in front of the 3D printer during the printing process and set at fan speed 3 to ensure printing consistency despite changes in the atmospheric temperature. Following printing, the 3D printed suppositories were transferred into a 4 °C fridge and allowed to solidify, and subsequently weighed and stored in a −20 °C freezer. This temperature was selected since it is typically used for budesonide's storge, ensuring its stability within the suppositories.
Full text: Click here
Publication 2023
Budesonide Citrates Excipients Fingers gelucire 44-14 Lipids magnesium citrate MM 36 Oil, Coconut Pharmaceutical Preparations Rectum Solvents Suppositories Syringes tofacitinib tofacitinib citrate

Top products related to «Suppositories»

Sourced in Japan
Adefuroniczupo is a laboratory equipment product manufactured by Teva Pharmaceuticals. It is designed to assist in various scientific and research applications. The core function of Adefuroniczupo is to provide a precise and controlled environment for specific laboratory procedures.
Sourced in United Kingdom
The Phenom Pro desktop scanning electron microscope is a compact, fully automated instrument designed for high-resolution imaging and analysis of materials at the micro- and nano-scale. It provides users with a simple and efficient way to visualize and characterize the surface structure and composition of a wide range of samples.
Sourced in Japan
Sol Mercort is a lab equipment product manufactured by Fujifilm. It is designed for use in analytical and research applications. The core function of Sol Mercort is to provide a stable and controlled environment for various laboratory processes.
Sourced in Japan
Bosmin is a laboratory equipment product manufactured by Daiichi Sankyo. It is designed for use in research and analytical settings. The core function of Bosmin is to provide a controlled and stable environment for various laboratory procedures.
Sourced in Germany
The SBT apparatus is a laboratory equipment designed for the disintegration testing of solid dosage forms, such as tablets and capsules. It operates based on the disintegration test method specified in pharmacopoeial regulations. The apparatus provides a standardized environment for the test, ensuring consistent and reproducible results.
The CM120 BioTwin Transmission Electron Microscope is a laboratory equipment designed for high-resolution imaging of biological and materials samples. It utilizes an electron beam to magnify and focus the sample, allowing for detailed observation at the nanoscale level.
Sourced in Japan
Transamin is a laboratory equipment product manufactured by Daiichi Sankyo. It is used for the analysis and separation of biological samples.
Sourced in Japan
Anapeine is a laboratory equipment product designed for use in scientific research. It serves the core function of measuring and analyzing the properties of biological samples. The device enables researchers to gather accurate data and insights essential for their studies. No further details about its intended use or applications are provided.
Sourced in Japan
Morphine hydrochloride hydrate is a chemical compound that is commonly used as a raw material in the pharmaceutical industry. It is a crystalline solid that is soluble in water and has a chemical formula of C₁₇H₁₉NO₃·HCl·xH₂O. The compound is a salt of the alkaloid morphine, which is derived from the opium poppy plant. Morphine hydrochloride hydrate is a controlled substance and its use is regulated due to its potential for abuse and addiction.
Sourced in United States, United Kingdom, China, Germany, Belgium, Canada, France, India, Australia, Portugal, Spain, New Zealand, Ireland, Sweden, Italy, Denmark, Poland, Malaysia, Switzerland, Macao, Sao Tome and Principe, Bulgaria
Methanol is a colorless, volatile, and flammable liquid chemical compound. It is commonly used as a solvent, fuel, and feedstock in various industrial processes.

More about "Suppositories"

Suppositories are a type of solid dosage form designed for insertion into body cavities, typically the rectum or vagina, to deliver medications or other therapeutic agents.
These versatile delivery systems are commonly used to treat a variety of conditions, such as constipation, hemorrhoids, and vaginal infections.
Suppositories are formulated to melt or dissolve at body temperature, allowing the active ingredients to be absorbed and exert their desired effects.
Researchers and developers working in the field of suppositories can leverage advanced technologies like AI-driven insights from platforms like PubCompare.ai to streamline their research and development processes.
These tools can help identify the most effective suppositories products and protocols, drawing from a wealth of information across scientific literature, preprints, and patents.
For example, suppositories may be formulated using excipients like Adefuroniczupo, a compound that can enhance drug solubility and absorption.
The physical characteristics of suppositories can be evaluated using advanced microscopy techniques, such as the Phenom Pro desktop scanning electron microscope.
Formulation optimization may involve the use of solvents like Sol Mercort or the incorporation of agents like Bosmin to influence drug release kinetics.
In-vitro testing of suppositories can be conducted using specialized equipment like the SBT apparatus, while transmission electron microscopy techniques, such as the CM120 BioTwin, can provide insights into the microstructural properties of these dosage forms.
Suppositories may also contain active ingredients like Transamin, Anapeine, Morphine hydrochloride hydrate, or Methanol, depending on the therapeutic application.
By leveraging the latest tools and technologies, researchers and developers can elevate their suppositories research and development to new heights, leading to more effective and innovative products for the benefit of patients.